Endpoints News
Cardio specialist's $400M haul Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Thu F
18 June, 2026
Manufacturing Day 2026
Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.
news
Biogen makes up to $1B deal for secretive anti-inflammatory biotech
ENDPOINTS NEWS
Kardigan raises $400M in IPO to back three clinical-stage cardio drugs
ENDPOINTS NEWS
Exclusive: Lilly's TuneLab crosses 100-member mark, adds AI models from buzzy startup Chai
ENDPOINTS NEWS
Antifungal from F2G, Shionogi succeeds in Phase 3 study
ENDPOINTS NEWS
Peer Review
Moderna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs
ENDPOINTS NEWS
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
in case you missed it
1.
After Makary's exit, FDA is giving CRL recipients another chance
ENDPOINTS NEWS
2.
FDA warns telehealth companies over compounded GLP-1s
ENDPOINTS NEWS
3.
UK waitlist for Novo's Wegovy pill triples in week after approval, major online pharmacy says
ENDPOINTS NEWS
4.
$25M ransom, no deal: Hackers claim Novo's drug recipes and AI models are for sale
ENDPOINTS NEWS
5.
In another reversal, FDA gives uniQure accelerated approval path for Huntington's gene therapy
ENDPOINTS NEWS
6.
Jazz turns to AbCellera for T cell engagers against GI cancers in up to $4.1B deal
ENDPOINTS NEWS
7.
Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs
ENDPOINTS NEWS
8.
Migraine biotech makes its debut with $46M to advance preclinical pipeline
ENDPOINTS NEWS
9.
Inside the push to keep RFK Jr.’s vaccine agenda alive
THE WASHINGTON POST
10.
BioNTech investor Förtsch says founders’ spinout raises concerns
BLOOMBERG
Elizabeth Cairns
.

Tomorrow is Juneteenth, a public holiday in the US, and Endpoints won't be sending our usual newsletters. We'll return on Monday, June 22. Have a great long weekend!

.
Elizabeth Cairns
Senior Biopharma Journalist, Endpoints News
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin
Worldwide made. Thanks for reading.